Clinical Trials Browser

Phase 1/2 × Blastic Plasmacytoid Dendritic Cell Neoplasm × tagraxofusp × Clear all

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Phase 1/2 Completed

138 enrolled 23 charts 2 FDA

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute